Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results
11 Juni 2020 - 11:15PM
Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an
immuno-oncology company developing innovative drug candidates for
the prevention and treatment of cancer, today announces that it
intends to rely on exemptions granted in Ontario Instrument 51-505
Temporary Exemption from Certain Corporate Finance Requirements
(the “Blanket Relief”) to extend the deadline for filing its
interim consolidated financial statements for the three and nine
month periods ended April 30, 2020, related management’s discussion
and analysis (“MD&A”) and related management certifications
(the “Interim Disclosure Documents”).
The Company would ordinarily be required to file
the Interim Disclosure Documents by June 15, 2020 under National
Instrument 51-102 Continuous Disclosure Obligations. In accordance
with the Blanket Relief, which provides up to a 45-day extension
for the filing of certain periodic disclosure documents, the
Company expects to file the Interim Disclosure Documents by July
30, 2020.
The Company confirms that its directors,
officers and other insiders will be subject to a trading blackout
under its Insider Trading and Inside Information Policy and
Procedures that reflects the principles of National Policy 11-207
Failure to File Cease Trading Orders and Revocations in Multiple
Jurisdictions until after the filing of the Interim Disclosure
Documents has been completed and the news release regarding the
financial results has been widely disseminated. The Company also
confirms that there have been no material developments to its
business since the Company last provided a business update on May
14, 2020.
About Helix BioPharma
Corp.Helix BioPharma Corp. is an immuno-oncology company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix’s
product development initiatives include its novel L-DOS47 new drug
candidate and Chimeric Antigen Receptor (“CAR”) based cell
therapies. Helix is currently listed on the TSX under the symbol
“HBP”.
Investor RelationsHelix
BioPharma Corp.9120 Leslie Street, Suite 205Richmond Hill, Ontario,
L4B 3J9Tel: 905-841-2300Email: ir@helixbiopharma.com
Cautionary StatementsThis news
release may contain forward-looking statements with respect to
Helix, its operations, strategy, financial performance and
condition, including its activities relating to its drug
development program, any anticipated timelines for the commencement
or completion of certain activities such as raising sufficient
capital, merger and acquisition activity, listing on a U.S.
exchange and other information in future periods. These statements
generally can be identified by use of forward-looking words such as
“aims”, “transform”, “should”, “may”, “will”, “expect”, “estimate”,
“anticipate”, “intends”, “believe” or “continue” or the negative
thereof or similar variations. The actual results and performance
of discussed herein could differ materially from those expressed or
implied by such statements. Such statements are qualified in their
entirety by the inherent risks and uncertainties surrounding future
expectations, including: (i) Helix’s ability to operate as a going
concern being dependent mainly on securing sufficient additional
financing in order to fund its ongoing research and development and
other operating activities; (ii) the generally inherent uncertainty
involved in scientific research and drug development and those
specific to Helix’s pre-clinical and clinical development programs
(DOS47, L-DOS47, V-DOS47 and CAR-T); (iii) that any transactions
contemplated herein are completed; and (iv) those risks and
uncertainties affecting Helix as more fully described in Helix’s
most recent Annual Information Form, which is available at
www.sedar.com (together, the “Helix Risk Factors”). Certain
material factors and assumptions are applied in making the
forward-looking statements, including, without limitation, that
sufficient financing will be obtained in a timely manner to allow
Helix to continue operations and implement its clinical trials in
the manner and on the timelines anticipated and that the Helix Risk
Factors will not cause Helix’s actual results or events to differ
materially from the forward-looking statements. These cautionary
statements qualify all such forward-looking statements.
Forward-looking statements and information are
based on the beliefs, assumptions, opinions, plans and expectations
of Helix’s management on the date of this news release, and the
Company does not assume any obligation to update any
forward-looking statement or information should those beliefs,
assumptions, opinions, plans or expectations, or other
circumstances change, except as required by law.
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Dez 2023 bis Dez 2024